Compare · CRMD vs OUST
CRMD vs OUST
Side-by-side comparison of CorMedix Inc. (CRMD) and Ouster Inc. (OUST): market cap, price performance, sector, and recent activity on the wire.
Summary
- CRMD operates in Health Care, while OUST operates in Industrials - the two are in different parts of the market.
- OUST is the larger of the two at $518.2M, about 3.3x CRMD ($155.0M).
- Over the past year, CRMD is down 34.7% and OUST is up 228.6% - OUST leads by 263.3 points.
- OUST has been more active in the news (17 items in the past 4 weeks vs 4 for CRMD).
- OUST has more recent analyst coverage (18 ratings vs 7 for CRMD).
- Company
- CorMedix Inc.
- Ouster Inc.
- Price
- $8.24+0.86%
- $43.93-4.56%
- Market cap
- $155.0M
- $518.2M
- 1M return
- +4.17%
- +55.95%
- 1Y return
- -34.71%
- +228.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 4
- 17
- Recent ratings
- 7
- 18
CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Ouster Inc.
Ouster, Inc. designs and manufactures digital lidar sensors for industrial automation, smart infrastructure, robotics, and automotive markets. Its product portfolio includes OS0, and ultra-wide view digital lidar; OS1, a mid-range digital lidar; OS2, a long-range digital lidar; and ES2 digital lidar. The company is based in San Francisco, California.
Latest CRMD
- Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
- SEC Form 10-Q filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
- SEC Form DEFA14A filed by CorMedix Inc.
- SEC Form DEF 14A filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
- SEC Form PRE 14A filed by CorMedix Inc.
Latest OUST
- Ouster and FieldAI Collaborate to Scale Autonomous Perception for the World's Most Challenging Environments with REV8 Digital Lidar
- SEC Form SD filed by Ouster Inc.
- Roth Capital initiated coverage on Ouster with a new price target
- Chief Revenue Officer Jacquemet Cyrille sold $377,320 worth of shares (9,433 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 123,158 units (SEC Form 4)
- Chief Technology Officer Frichtl Mark exercised 50,063 shares at a strike of $14.22 and sold $15,606,971 worth of shares (384,426 units at $40.60) as part of a pre-agreed trading plan, decreasing direct ownership by 53% to 294,924 units (SEC Form 4)
- Chief Operating Officer Spencer Darien sold $1,350,022 worth of shares (30,000 units at $45.00) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 342,366 units (SEC Form 4)
- SEC Form 144 filed by Ouster Inc.
- ARGUS Interception and Ouster Announce Strategic Agreement to Strengthen the Precision and Reliability of Counter-UAS Systems with Digital Lidar
- Director Heystee Susan sold $324,243 worth of shares (9,316 units at $34.80), decreasing direct ownership by 21% to 35,094 units (SEC Form 4)
- Chief Revenue Officer Jacquemet Cyrille sold $350,000 worth of shares (10,000 units at $35.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 132,590 units (SEC Form 4)